A study of 20 SLE patients with intravenous immunoglobulin - Clinical and serologic response

Lupus

Volumn 8, Issue 9, 1999, Pages 705-712

  Levy, Yair ^a   Sherer, Yaniv ^a   Ahmed, Alaa ^b   Langevitz, Pnina ^f   George, Jacob ^a   Fabbrizzi, Fabrizio ^c   Terryberry, Jeff ^b   Meissner, Martyna ^d   Lorber, Margalit ^e   Peter, James B ^b   Shoenfeld, Yehuda ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b Specialty Laboratories   (United States)

^c Clinical Trial Consultant   (Italy)

^d INSTITUTE OF RHEUMATOLOGY   (Poland)

^e RAMBAM MEDICAL CENTER   (Israel)

^f NONE

Author keywords

Autoantibodies; Idiotypes; Intravenous immunoglobulin; Systemic lupus erythematosus

Indexed keywords

ANTIGEN; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; CELL NUCLEUS ANTIGEN; COMPLEMENT; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; DOUBLE STRANDED DNA; IMMUNOGLOBULIN; PREDNISOLONE;

ADULT; ARTHRITIS; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE ACTIVITY; DRUG EFFICACY; FEMALE; FEVER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUROPSYCHIATRY; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA;

EID: 0032728801     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/096120399678841007     Document Type: Article

References (63)

1. Kazatchkine MD, Morell A (eds). Intravenous Immunoglobulin Research and Therapy. Parthenon Publishing: New York, 1996.
2. Krause I, Blank M, Kopolovic J et al. Abrogation of experimental systemic lupus erythematosus and primary antiphospholipid syndrome with intravenous gamma globulin. J Rheumatol 1995; 22: 1068-1074.
3. Carp HJA, Ahiron R, Mashiach S et al. Intravenous immunoglobulin in women with five or more abortions. Am J Reprod Immunol 1996; 35: 360-362.
4. Tomer Y, Shoenfeld Y. Successful treatment of psychosis secondary to SLE with high dose intravenous immunoglobulin. Clin Exp Rheumatol 1992; 10: 391-393.
5. Bakimer R, Guilburd B, Zurgil N, Shoenfeld Y. The effect of intravenous γ-globulin on the induction of experimental antiphospholipid syndrome. Clin Immunol Imnnmopathol 1993; 69: 97-102.
6. Shoenfeld Y, Krause I, Blank M. New methods of treatment in an experimental murine model of systemic lupus erythematosus induced by idiotypic manipulation. Ann Rheum Dis 1997; 56: 5-11.
7. Levy Y, George J, Langewitch P et al. Novel aspects of IVIg treatment in autoimmune diseases. In: Proceedings of the XIX ILAR Congress of Rheumatology, 1997 June 8-13, Singapore, pp. 456-458.
8. Winder A, Shoenfeld Y, Hochman R et al. High dose intravenous gammaglobulin for heparin induced thrombocytopenia: a prompt response. J Clin Immunol 1998; 18: 330-334.
9. Shoenfeld Y, Krause I. Immunosuppression and immunomodulation of experimental systemic lupus erythematosus and antiphospholipid syndrome. Transplant Proc 1996; 28: 3096-3098.
10. Corvetta A, Della Bitta R, Gabriella A et al. Use of high-dose intravenous immunoglobulin in systemic lupus erythematosus: report of three cases. Clin Exp Rheumatol 1989; 7: 295-299.
11. Lin CY, Hsu HC, Chiang H. Improvement of histological and immunological change in steroid and immunosuppressive drug-resistant lupus nephritis by high-dose intravenous gamma globulin. Nephron 1989; 53: 303-310.
12. Schroeder JO, Zeuner RA, Euler HH, Loffler H. High dose intravenous immunoglobulins in systemic lupus erythematosus: clinical and serological results of a pilot study. J Rheumatol 1996; 23: 71-75.
13. Francioni C, Galeazzi M, Fioravanti A et al. Long term IVIg treatment in systemic lupus erythematosus. Clin Exp Rheum 1994; 12: 163-168.
14. Maier WP, Gordon DS, Howard RF et al. Intravenous immunoglobulin therapy in systemic lupus erythematosus-associated thrombocytopenia. Arthritis Rheum 1990; 33: 1233-1239.
15. De Pita O, Bellucci AM, Ruffelli M et al. Intravenous immunoglobulin therapy is not able to efficiently control cutaneous manifestations in patients with lupus erythematosus. Lupus 1997; 6: 415-417.
16. Aharon A, Levy Y, Bar-Dayan Y et al. Successful treatment of early secondary myelofibrosis in SLE with IVIg. Lupus 1997; 6: 408-411.
17. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
18. Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989; 32: 1107-1118.
19. Hollingworth PN, Pummer SC, Dawkins RL. Antinuclear antibodies. In: Peter JP, Shoenfeld Y (eds). Autoantibodies. Elsevier: Amsterdam, 1996, pp. 74-90.
20. Swaak AJG, Smeenk R. Detection of anti-dsDNA as a diagnostic tool: a prospective study in 441 non-systemic lupus erythematosus patients with anti-dsDNA antibody. Ann Rheum Dis 1985; 44: 245-251.
21. Barka N, Shen GQ, Shoenfeld Y et al. Multireactive pattern of serum autoantibodies in asymptomatic individuals with immunoglobulin A deficiency. Clin Diag Lab Immunol 1995; 2: 469-472.
22. Gregorio GV, Davies ET, Mieli-Vergani G, Vergani D. Significance of extractable nuclear antigens in childhood autoimmune liver diseases. Clin Exp Immunol 1995; 102: 308-313.
23. Marmont AM. Intravenous immunoglobulin in immune thrombocytopenia. Lancet 1983; 2: 577-578 (letter).
24. Akashi K., Nagasawa K, Mayumi T et al. Successful treatment of refractory systemic lupus erythematosus with intravenous immunoglobulins. J Rheumatol 1990; 17: 375-379.
25. Ben-Chetrit E, Putterman C, Naparstek Y. Lupus refractory pleural effusion: transient response to intravenous immunoglobulins. J Rheumatol 1991; 18: 1635-1637.
26. Ben-Chetrit E, Putterman C. Transient neutropenia induced by intravenous immune globulin. New Engl J Med 1992; 326: 270-271.
27. Hjortkjoer Petersen H, Nielsen H, Hansen M et al. High-dose immunoglobulin therapy in pericarditis caused by SLE. Scand J Rheumatol 1990; 19: 91-93.
28. Oliet A, Hernandez E, Gallar P, Vigil A. High-dose intravenous gamma-globulin in systemic lupus erythematosus. Nephron 1992; 62: 465 (letter).
29. Winder A, Molad Y, Ostfeld I et al Treatment of systemic lupus erythematosus by prolonged administration of high dose intravenous immunoglobulin: report of 2 cases. J Rheumatol 1993; 20: 495-498.
30. Ilan Y, Naparstek Y. Pure red cell aplasia associated with systemic lupus etythematosus: remission after a single course of intravenous immunoglobulin. Acta Haematol 1993, 89: 152-154.
31. Bingisser R, Speich R, Fontana A et al. Lupus erythematosus and Miller-Fisher syndrome. Arch Neurol 1994; 51: 828-830.
32. Aharon A, Zandman-Goddard G, Shoenfeld Y. Autoimmune multiorgan involvement in elderly men is it SLE? Clin Rheumatol 1994; 13: 631-634.
33. Strufelt G, Mousa F, Jonsson H et al. Recurrent cerebral infarction and the antiphospholipid syndrome: effect of intravenous gammaglobulin in a patient with systemic lupus erythematosus. Ann Rheum Dis 1990; 49: 939-941.
34. Roldan R, Roman J, Lopez D et al. Treatment of hemolytic anemia and severe thrombocytopenia with high-dose methylprednisolone and intravenous immunoglobulins in SLE. Scand J Rheumatol 1994; 23: 218-219.
35. Ruiz-Valverde MP, Segarra A, Tovar JL, Piera L. Treatment of systemic lupus erythematosus-associated thrombocytopenia with intravenous gamma globulin. Nephron 1994; 67: 500-501.
36. Becker BN, Fuchs H, Hakim R. Intravenous immune globulin in the treatment of patients with systemic lupus erythematosus and end-stage renal disease. J Am Soc Nephrol 1995; 5: 1746-1750.
37. Welch TR, McAdams AJ, Beischel LS. Glomerulonephritis associated with complete deficiency of the fourth component of complement. Response to intravenous immunoglobulin. Arthritis Rheum 1995; 38: 1333-1337.
38. Gaedicke G, Teller WM, Kohne E et al. IgG therapy in systemic lupus erythematosus - two case reports. Blut 1984; 48: 387-390.
39. Lesprit P, Mouloud F, Bierling P et al. Prolonged remission of SLE-associated polyradiculoneuropathy after a single course of intravenous immunoglobulin. Scand J Rheumatol 1996; 25: 177-179.
40. Hashkes PJ, Lovell DJ. Vasculitis in systemic lupus erythematosus following intravenous immunoglobulin therapy. Clin Exp Rheumatol 1996; 14: 673-675.
41. Lafferty TE, Smith JB, Schuster SJ, DeHoratius RJ. Treatment of acquired factor VIII inhibitor using intravenous immunoglobulin in two patients with systemic lupus erythematosus. Arthritis Rheum 1997; 40: 775-778.
42. Disla E, Rhim HR, Reddy A et al. Reversible cardiogenic shock in a patient with lupus myocarditis. J Rheumatol 1993; 20: 2174 (letter).
43. Sherer Y, Levy Y, Langevitz P, Lorber M et al. Successful treatment of systemic lupus erythematosus cerebritis with intravenous immunoglobulin. Clin Rheumatol 1999; 18: 170-173.
44. Sherer Y, Levy Y, Shoenfeld Y. Marked improvement of severe cardiac dysfunction after one course of intravenous immunoglobulin in a patient with systemic lupus erythematosus. Clin Rheumatol 1999; 18: 238-240.
45. Sherer Y, Langevitz P, Levy Y et al Treatment of chronic bilateral pleural effusions with intravenous immunoglobulin and cyclosporin. Lupus 1999; 8: 324-327.
46. Salmun LM, Barlan I, Wolf HM et al. Effect of intravenous immunoglobulin on steroid consumption in patients with severe asthma: a double-blind, placebo-controlled, randomized trial. J Allergy Clin Immunol 1999; 103: 810-815.
47. Ballow M. Mechanisms of action of intravenous immunoglobulin: clinical implications in autoimmune and inflammatory diseases. In: Kazatchkine MD, Morell A (eds). Intravenous Immunoglobulin Research and Therapy. Parthenon Publishing: New York, 1996, pp. 123-128.
48. Krause I, Blank M, Shoenfeld Y. Anti-DNA and antiphospholipid antibodies in IVIg preparations: In vivo study in naive mice. J Clin Immunol 1998; 18: 52-60.
49. Silvestris F, Cafforio P, Dammacco F. Pathogenic anti-DNA idiotype-reactive IgG in intravenous immunoglobulin preparations. Clin Exp Immunol 1994; 97: 19-25.
50. DeKeyser F, DeKeyser H, Kazatchkine MD et al. Pooled human immunoglobulins contain anti-idiotypes with reactivity against the SLE-associated 4B4 cross-reactive idiotype. Clin Exp Rheumatol 1996; 14: 587-591.
51. Evans MJ, Suenaga R, Abdou NI. Detection and purification of anti-idiotypic antibody against anti-DNA in intravenous immune globulin. J Clin Immunol 1991; 11: 291-295.
52. Caccavo D, Vaccaro F, Ferri GM et al. Anti-idiotypes against antiphospholipid antibodies are present in normal polyspecific immunoglobulins for therapeutic use. J Autoimmun 1994; 7: 537-548.
53. Evans M, Abdou NI. In vitro modulation of anti-DNA secreting peripheral blood mononuclear cells of lupus patients by anti-idiotypic antibody of pooled human intravenous immune globulin. Lupus 1993; 2: 371-375.
54. Silvestris F, D'Amore O, Cafforio P et al. Intravenous immune globulin therapy of lupus nephritis: use of pathogenic anti-DNA-reactive IgG. Clin Exp Immunol 1996; 104 Suppl 1: 91-97.
55. Mendlovic S, Brocke S, Shoenfeld Y et al. Induction of SEE-like disease in mice by a common anti-DNA idiotype. Proc Natl Acad Sci USA 1988; 85: 2260-2264.
56. Lockwood CM. Intravenous immunoglobulin for the treatment of vasculitides. In: Kazatchkine MD, Morell A (eds). Intravenous Immunoglobulin Research and Therapy. Parthenon Publishing: New-York, 1996, pp. 143-146.
57. Lafferty TE, DeHoratius RJ, Bruce Smith J. Aseptic meningitis as a side effect of intravenous immune gammaglobulin. J Rheumatol 1997; 24: 2491-2492.
58. Schifferli J, Leski M, Farve H et al. High-dose intravenous IgG treatment and renal function. Lancet 1991; 337: 457-458.
59. Blanco R, Gonzalez-Gay MA, Ibanez D et al. Paradoxical and persistent renal impairment in Henoch-Schonlein purpura after high-dose immunoglobulin therapy. Nephron 1997; 76: 247-248 (letter).
60. Pasatiempo AMG, Kroser JA, Rudnick M, Hoffmann BI. Acute renal failure after intravenous immunoglobulin therapy. J Rheumatol 1994; 21: 347-349.
61. Jordan SC. Intravenous γ-globulin therapy in systemic lupus erythematosus and immune complex disease. Clin Immunol Immunopathol 1989; 53: 164-169.
62. Kurlander R, Coleman RE, Moore J et al. Comparison of the efficacy of a two-day and a five-day schedule for infusing intravenous gamma globulin in the treatment of immune thrombocytopenic purpura in adults. Am J Med 1987; 83: 17-24.
63. Onouchi Z, Yanagisawa M, Hirayama T et al. Optimal dosage and differences in therapeutic efficacy of IVIg in Kawasaki disease. Acta Paediatr Jpn 1995; 37: 40-46.